ABT
Abbott Laboratories · Healthcare · Medical - Devices
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q2 2024
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 182 | 0 | 1.10B | $99.82B | +5 | −4 |
| Q1 2026 | 184 | +3 | 1.11B | $114.25B | +7 | −5 |
| Q4 2025 | 180 | +2 | 1.17B | $146.24B | +3 | — |
| Q3 2025 | 24 | 0 | 623.34M | $83.47B | +1 | −2 |
| Q2 2025 | 22 | 0 | 527.92M | $71.78B | +1 | −1 |
| Q1 2025 | 19 | 0 | 196.20M | $26.01B | +1 | −1 |
| Q4 2024 | 19 | -1 | 182.48M | $20.63B | — | −1 |
| Q3 2024 | 19 | 0 | 108.33M | $12.33B | +1 | −1 |
| Q2 2024 | 19 | — | 110.87M | $11.51B | — | — |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passiv) | 34.41M | — | $3.57B | 0.3% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passiv) | 34.41M | — | $3.57B | 0.3% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 25.53M | — | $2.65B | 0.5% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 25.53M | — | $2.65B | 0.5% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 25.53M | — | $2.65B | 0.5% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 25.53M | — | $2.65B | 0.5% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 25.53M | — | $2.65B | 0.5% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 25.53M | — | $2.65B | 0.5% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 25.53M | — | $2.65B | 0.5% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 25.53M | — | $2.65B | 0.5% | n/c | 1 | SEC ↗ |
| 11 | Norges Bank ✦ (passiv) | 20.36M | — | $2.12B | 0.3% | n/c | 1 | SEC ↗ |
| 12 | Fisher Asset Management ✦ | 10.52M | — | $1.09B | 0.5% | n/c | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 4.06M | — | $422.13M | 0.1% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 4.06M | — | $422.13M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 2.38M | — | $247.25M | 0.6% | n/c | 1 | SEC ↗ |
| 16 | Millennium Management ✦ | 2.33M | — | $241.93M | 0.2% | n/c | 1 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 2.30M | — | $239.03M | 0.2% | n/c | 1 | SEC ↗ |
| 18 | Bridgewater Associates ✦ | 1.67M | — | $173.37M | 0.9% | n/c | 1 | SEC ↗ |
| 19 | Adage Capital Partners ✦ | 1.65M | — | $171.94M | 0.3% | n/c | 1 | SEC ↗ |
| 20 | Renaissance Technologies ✦ | 1.56M | — | $162.35M | 0.3% | n/c | 1 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 1.02M | — | $105.87M | 0.2% | n/c | 1 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 1.02M | — | $105.87M | 0.2% | n/c | 1 | SEC ↗ |
| 23 | Citadel Advisors ✦ | 983.92K | — | $102.24M | 0.1% | n/c | 1 | SEC ↗ |
| 24 | Citadel Advisors ✦ | 983.92K | — | $102.24M | 0.1% | n/c | 1 | SEC ↗ |
| 25 | PRIMECAP Management ✦ | 930.93K | — | $96.73M | 0.1% | n/c | 1 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 871.20K | — | $90.42M | 0.1% | n/c | 1 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 871.20K | — | $90.42M | 0.1% | n/c | 1 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 871.20K | — | $90.42M | 0.1% | n/c | 1 | SEC ↗ |
| 29 | Marshall Wace ✦ | 216.34K | — | $22.48M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Gotham Asset Management ✦ | 34.73K | — | $3.61M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | GAMCO Investors ✦ | 22.96K | — | $2.39M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Dodge & Cox ✦ | 17.86K | — | $1.86M | 0.0% | n/c | 1 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| Keine neu erfassten Käufer in diesem Quartal. |
Ausgestiegen
| Keine erfassten Ausstiege in diesem Quartal. |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 3,058 Inhaber, 1.35B Anteile, $133.47B gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Käufe auf dem offenen Markt (P)
Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.
Verkäufe auf dem offenen Markt (S)
Officer · 5.85K Ant. · $642,506
Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik